Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection

M. Spina, S. Sandri, D. Serraino, C. Gobitti, M. Fasan, A. Sinicco, P. L. Garavelli, A. Ridolfo, U. Tirelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Incidence and mortality of AIDS patients have significantly declined in the developed countries due to the very active anti-HIV combination therapy available today. Because of the prolongation of the survival expectancy of these patients, other non-AIDS defining tumours have been recently reported in several cohort studies with increased frequency. We want to report the clinico-pathological features and the outcome of 39 patients with lung cancer and HIV infection, collected by the Italian Cooperative Group on AIDS and Tumors (GICAT) between 1986 and December 1997. As a control group, we decided to evaluate patients, less than 60 years of age, with lung cancer but without HIV infection seen at the CRO, Aviano, during 1995 and 1996. The median age of the study group patients was 38 years (range 28-58) and 90% of them were males. Sixty-nine percent of patients were intravenous drug users and HIV infection was asyntomatic in 41% of patients. NSCLC was observed in 78% of patients, SCLC in 13% and mesothelioma in 8%. Among NSCLC, adenocarcinoma was the most frequently observed histological subtype (48%). No differences were found as regards the stage of disease at diagnosis and the histologic subtype in comparison with the control group. The median overall survival was significantly shorter for patients with HIV infection when compared to that of the control group (5 months vs. 10 months, P <0.0001). In conclusion, the outcome of patients with SNCLC and HIV infection seems worse than that of the general population, suggesting a synergistic and/or addictive adverse effect of HIV on the outcome of lung cancer.

Original languageEnglish
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 5
Publication statusPublished - 1999

Fingerprint

Non-Small Cell Lung Carcinoma
HIV Infections
Therapeutics
Lung Neoplasms
Control Groups
Acquired Immunodeficiency Syndrome
HIV
Survival
Mesothelioma
Drug Users
Developed Countries
Neoplasms
Adenocarcinoma
Cohort Studies
Age Groups
Mortality
Incidence

Keywords

  • HIV infection
  • Lung cancer
  • Non-small cell lung cancer
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. / Spina, M.; Sandri, S.; Serraino, D.; Gobitti, C.; Fasan, M.; Sinicco, A.; Garavelli, P. L.; Ridolfo, A.; Tirelli, U.

In: Annals of Oncology, Vol. 10, No. SUPPL. 5, 1999.

Research output: Contribution to journalArticle

Spina, M, Sandri, S, Serraino, D, Gobitti, C, Fasan, M, Sinicco, A, Garavelli, PL, Ridolfo, A & Tirelli, U 1999, 'Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection', Annals of Oncology, vol. 10, no. SUPPL. 5.
Spina, M. ; Sandri, S. ; Serraino, D. ; Gobitti, C. ; Fasan, M. ; Sinicco, A. ; Garavelli, P. L. ; Ridolfo, A. ; Tirelli, U. / Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. In: Annals of Oncology. 1999 ; Vol. 10, No. SUPPL. 5.
@article{44e1b078ad944b7dac532ba7e76f025c,
title = "Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection",
abstract = "Incidence and mortality of AIDS patients have significantly declined in the developed countries due to the very active anti-HIV combination therapy available today. Because of the prolongation of the survival expectancy of these patients, other non-AIDS defining tumours have been recently reported in several cohort studies with increased frequency. We want to report the clinico-pathological features and the outcome of 39 patients with lung cancer and HIV infection, collected by the Italian Cooperative Group on AIDS and Tumors (GICAT) between 1986 and December 1997. As a control group, we decided to evaluate patients, less than 60 years of age, with lung cancer but without HIV infection seen at the CRO, Aviano, during 1995 and 1996. The median age of the study group patients was 38 years (range 28-58) and 90{\%} of them were males. Sixty-nine percent of patients were intravenous drug users and HIV infection was asyntomatic in 41{\%} of patients. NSCLC was observed in 78{\%} of patients, SCLC in 13{\%} and mesothelioma in 8{\%}. Among NSCLC, adenocarcinoma was the most frequently observed histological subtype (48{\%}). No differences were found as regards the stage of disease at diagnosis and the histologic subtype in comparison with the control group. The median overall survival was significantly shorter for patients with HIV infection when compared to that of the control group (5 months vs. 10 months, P <0.0001). In conclusion, the outcome of patients with SNCLC and HIV infection seems worse than that of the general population, suggesting a synergistic and/or addictive adverse effect of HIV on the outcome of lung cancer.",
keywords = "HIV infection, Lung cancer, Non-small cell lung cancer, Survival, Treatment",
author = "M. Spina and S. Sandri and D. Serraino and C. Gobitti and M. Fasan and A. Sinicco and Garavelli, {P. L.} and A. Ridolfo and U. Tirelli",
year = "1999",
language = "English",
volume = "10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection

AU - Spina, M.

AU - Sandri, S.

AU - Serraino, D.

AU - Gobitti, C.

AU - Fasan, M.

AU - Sinicco, A.

AU - Garavelli, P. L.

AU - Ridolfo, A.

AU - Tirelli, U.

PY - 1999

Y1 - 1999

N2 - Incidence and mortality of AIDS patients have significantly declined in the developed countries due to the very active anti-HIV combination therapy available today. Because of the prolongation of the survival expectancy of these patients, other non-AIDS defining tumours have been recently reported in several cohort studies with increased frequency. We want to report the clinico-pathological features and the outcome of 39 patients with lung cancer and HIV infection, collected by the Italian Cooperative Group on AIDS and Tumors (GICAT) between 1986 and December 1997. As a control group, we decided to evaluate patients, less than 60 years of age, with lung cancer but without HIV infection seen at the CRO, Aviano, during 1995 and 1996. The median age of the study group patients was 38 years (range 28-58) and 90% of them were males. Sixty-nine percent of patients were intravenous drug users and HIV infection was asyntomatic in 41% of patients. NSCLC was observed in 78% of patients, SCLC in 13% and mesothelioma in 8%. Among NSCLC, adenocarcinoma was the most frequently observed histological subtype (48%). No differences were found as regards the stage of disease at diagnosis and the histologic subtype in comparison with the control group. The median overall survival was significantly shorter for patients with HIV infection when compared to that of the control group (5 months vs. 10 months, P <0.0001). In conclusion, the outcome of patients with SNCLC and HIV infection seems worse than that of the general population, suggesting a synergistic and/or addictive adverse effect of HIV on the outcome of lung cancer.

AB - Incidence and mortality of AIDS patients have significantly declined in the developed countries due to the very active anti-HIV combination therapy available today. Because of the prolongation of the survival expectancy of these patients, other non-AIDS defining tumours have been recently reported in several cohort studies with increased frequency. We want to report the clinico-pathological features and the outcome of 39 patients with lung cancer and HIV infection, collected by the Italian Cooperative Group on AIDS and Tumors (GICAT) between 1986 and December 1997. As a control group, we decided to evaluate patients, less than 60 years of age, with lung cancer but without HIV infection seen at the CRO, Aviano, during 1995 and 1996. The median age of the study group patients was 38 years (range 28-58) and 90% of them were males. Sixty-nine percent of patients were intravenous drug users and HIV infection was asyntomatic in 41% of patients. NSCLC was observed in 78% of patients, SCLC in 13% and mesothelioma in 8%. Among NSCLC, adenocarcinoma was the most frequently observed histological subtype (48%). No differences were found as regards the stage of disease at diagnosis and the histologic subtype in comparison with the control group. The median overall survival was significantly shorter for patients with HIV infection when compared to that of the control group (5 months vs. 10 months, P <0.0001). In conclusion, the outcome of patients with SNCLC and HIV infection seems worse than that of the general population, suggesting a synergistic and/or addictive adverse effect of HIV on the outcome of lung cancer.

KW - HIV infection

KW - Lung cancer

KW - Non-small cell lung cancer

KW - Survival

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032692747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032692747&partnerID=8YFLogxK

M3 - Article

C2 - 10582147

AN - SCOPUS:0032692747

VL - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -